Glaucoma Therapeutics Market By Disease Type, Drug Class and End User - Global Industry Analysis And Forecast To 2025

Published On : February 2019 Pages : 170 Category: Pharmaceuticals Report Code : HC022550

Glaucoma Therapeutics Market By Disease Type (Primary Angle Closure Glaucoma (PACG) and Primary Open Angle Glaucoma (POAG)), Drug Class (Fixed-Dose Combinations, Alpha Adrenergic Agonist, Combined Medication, Beta Blockers, Cholinergic, Prostaglandin Analogs and Carbonic Anhydrase Inhibitor) and End User (Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals and Other End User) - Global Industry Analysis And Forecast To 2025        

Industry Outlook

Glaucoma is a type of disease that is related to the eyes, in this disease the fluid pressure in the eyes increases, if this condition is not treated then the patient suffering can lose vision & can also get blind. The disease is very common in aged people which cause damage to the optical nerve. The disease affects both the eyes but one of them can be severely damaged. The use of therapeutics for Glaucoma is growing due to factors like; rising number of people suffering from the diseases, rising number of cases of blindness, increasing number of aged population across the globe, increases in diabetes is increasing the risk of getting affected by the disease, improvement in the healthcare sector across the globe, emergence of combination therapy for the treatment, etc. Therefore, the Glaucoma Therapeutics Market is anticipated to expand and has tremendous scope during the forecast period. The global Glaucoma Therapeutics Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

The global Glaucoma Therapeutics Market is based on segment, by Disease Type the market is segmented into Primary Angle Closure Glaucoma (PACG) and Primary Open Angle Glaucoma (POAG), by Drug Class the market is segmented into Fixed-Dose Combinations, Alpha Adrenergic Agonist, Combined Medication, Beta Blockers, Cholinergic, Prostaglandin Analogs and Carbonic Anhydrase Inhibitor, and by End User the market is segmented into Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals and Other End User.

  • Glaucoma Therapeutics Market, By Disease Type
  • Primary Angle Closure Glaucoma (PACG)
  • Primary Open Angle Glaucoma (POAG)
  • Glaucoma Therapeutics Market, By Drug Class
  • Fixed-Dose Combinations
  • Alpha Adrenergic Agonist
  • Combined Medication
  • Beta Blockers
  • Cholinergic
  • Prostaglandin Analogs
  • Carbonic Anhydrase Inhibitor
  • Glaucoma Therapeutics Market, By End User
  • Ambulatory Surgical Centers
  • Ophthalmic Clinics
  • Hospitals
  • Other End User

Regional Insights

On a global front, the Glaucoma Therapeutics Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). North American region is leading the global market owing to factors like; increasing cases of diabetes & ocular disorder and rising number of visually impaired & blind people.

Glaucoma Therapeutics Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The leading players in the market are Pfizer Inc., Valeant Pharmaceuticals International Inc., Novartis AG, Allergan Inc., Aerie Pharmaceuticals, Merck KGaA, Santen Pharmaceutical Co. Ltd., Fera Pharmaceuticals LLC., Aristo Pharmaceuticals Pvt. Ltd. and Teva Pharmaceutical Industries Ltd. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Pfizer Inc.
  • Valeant Pharmaceuticals International Inc.
  • Novartis AG
  • Allergan Inc.
  • Aerie Pharmaceuticals
  • Merck KGaA
  • Santen Pharmaceutical Co. Ltd.
  • Fera Pharmaceuticals LLC
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Teva Pharmaceutical Industries Ltd.

Some of the key questions answered by the report are:          

  • What was the market size in 2014 and forecast from 2015 to 2025?
  • What will be the industry market growth from 2015 to 2025?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Glaucoma Therapeutics Market, By Disease Type, Estimates and Forecast, 2014-2025 ($Million)

o   Primary Angle Closure Glaucoma (PACG)

o   Primary Open Angle Glaucoma (POAG)

o   Glaucoma Therapeutics Market, By Drug Class, Estimates and Forecast, 2014-2025 ($Million)

o   Fixed-Dose Combinations

o   Alpha Adrenergic Agonist

o   Combined Medication

o   Beta Blockers

o   Cholinergic

o   Prostaglandin Analogs

o   Carbonic Anhydrase Inhibitor

o   Glaucoma Therapeutics Market, By End User, Estimates and Forecast, 2014-2025 ($Million)

o   Ambulatory Surgical Centers

o   Ophthalmic Clinics

o   Hospitals

o   Other End User

 

o   Glaucoma Therapeutics Market, By Region, Estimates and Forecast, 2014-2025 ($Million)

o   North America

§  North America Glaucoma Therapeutics Market, By Country

o   U.S. Glaucoma Therapeutics Market

o   Canada Glaucoma Therapeutics Market

o   Mexico Glaucoma Therapeutics Market

o   Europe

§  Europe Glaucoma Therapeutics Market, By Country

o   Germany Glaucoma Therapeutics Market

o   UK Glaucoma Therapeutics Market

o   France Glaucoma Therapeutics Market

o   Russia Glaucoma Therapeutics Market

o   Italy Glaucoma Therapeutics Market

o   Rest of Europe Glaucoma Therapeutics Market

o   Asia-Pacific

§  Asia-Pacific Glaucoma Therapeutics Market, By Country

o   China Glaucoma Therapeutics Market

o   Japan Glaucoma Therapeutics Market

o   South Korea  Glaucoma Therapeutics Market

o   India Glaucoma Therapeutics Market

o   Southeast Asia Glaucoma Therapeutics Market

o   Rest of Asia-Pacific Glaucoma Therapeutics Market

o   South America

§  South America Glaucoma Therapeutics Market, By Country

o   Brazil Glaucoma Therapeutics Market

o   Argentina Glaucoma Therapeutics Market

o   Columbia Glaucoma Therapeutics Market

o   Rest of South America Glaucoma Therapeutics Market

o   Middle East and Africa

§  Middle East and Africa Glaucoma Therapeutics Market, By Country

o   Saudi Arabia Glaucoma Therapeutics Market

o   UAE Glaucoma Therapeutics Market

o   Egypt Glaucoma Therapeutics Market

o   Nigeria Glaucoma Therapeutics Market

o   South Africa Glaucoma Therapeutics Market

o   Rest of MEA Glaucoma Therapeutics Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2014-2025)

4.1.2.  Canada Market Status and Outlook (2014-2025)

4.1.3.  Mexico Market Status and Outlook (2014-2025)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2014-2025)

4.2.2.  France Market Status and Outlook (2014-2025)

4.2.3.  UK Market Status and Outlook (2014-2025)

4.2.4.  Russia Market Status and Outlook (2014-2025)

4.2.5.  Italy Market Status and Outlook (2014-2025)

4.2.6.  Rest of Europe Market Status and Outlook (2014-2025)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2014-2025)

4.3.2.  Japan Market Status and Outlook (2014-2025)

4.3.3.  Korea Market Status and Outlook (2014-2025)

4.3.4.  India Market Status and Outlook (2014-2025)

4.3.5.  Southeast Asia Market Status and Outlook (2014-2025)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2014-2025)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2014-2025)

4.4.2.  Argentina Market Status and Outlook (2014-2025)

4.4.3.  Columbia Market Status and Outlook (2014-2025)

4.4.4.  Rest of South America Market Status and Outlook (2014-2025)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2014-2025)

4.5.2.  United Arab Emirates Market Status and Outlook (2014-2025)

4.5.3.  Egypt Market Status and Outlook (2014-2025)

4.5.4.  Nigeria Market Status and Outlook (2014-2025)

4.5.5.  South Africa Market Status and Outlook (2014-2025)

4.5.6.  Turkey Market Status and Outlook (2014-2025)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2014-2025)

5.       Glaucoma Therapeutics Market, By Disease Type

5.1.     Introduction

5.2.     Global Glaucoma Therapeutics Revenue and Market Share by Disease Type (2014-2018)

5.2.1.  Global Glaucoma Therapeutics Revenue and Revenue Share by Disease Type (2014-2018)

5.3.     Primary Angle Closure Glaucoma (PACG)

5.3.1.  Global Primary Angle Closure Glaucoma (PACG) Revenue and Growth Rate (2014-2018)

5.4.     Primary Open Angle Glaucoma (POAG)

5.4.1.  Global Primary Open Angle Glaucoma (POAG) Revenue and Growth Rate (2014-2018)

6.       Glaucoma Therapeutics Market, By Drug Class

6.1.     Introduction

6.2.     Global Glaucoma Therapeutics Revenue and Market Share by Drug Class (2014-2018)

6.2.1.  Global Glaucoma Therapeutics Revenue and Revenue Share by Drug Class (2014-2018)

6.3.     Fixed-Dose Combinations

6.3.1.  Global Fixed-Dose Combinations Revenue and Growth Rate (2014-2018)

6.4.     Alpha Adrenergic Agonist

6.4.1.  Global Alpha Adrenergic Agonist Revenue and Growth Rate (2014-2018)

6.5.     Combined Medication

6.5.1.  Global Combined Medication Revenue and Growth Rate (2014-2018)

6.6.     Beta Blockers

6.6.1.  Global Beta Blockers Revenue and Growth Rate (2014-2018)

6.7.     Cholinergic

6.7.1.  Global Cholinergic Revenue and Growth Rate (2014-2018)

6.8.     Prostaglandin Analogs

6.8.1.  Global Prostaglandin Analogs Revenue and Growth Rate (2014-2018)

6.9.     Carbonic Anhydrase Inhibitor

6.9.1.  Global Carbonic Anhydrase Inhibitor Revenue and Growth Rate (2014-2018)

7.       Glaucoma Therapeutics Market, By End User

7.1.     Introduction

7.2.     Global Glaucoma Therapeutics Revenue and Market Share by End User (2014-2018)

7.2.1.  Global Glaucoma Therapeutics Revenue and Revenue Share by End User (2014-2018)

7.3.     Ambulatory Surgical Centers

7.3.1.  Global Ambulatory Surgical Centers Revenue and Growth Rate (2014-2018)

7.4.     Ophthalmic Clinics

7.4.1.  Global Ophthalmic Clinics Revenue and Growth Rate (2014-2018)

7.5.     Hospitals

7.5.1.  Global Hospitals Revenue and Growth Rate (2014-2018)

7.6.     Other End User

7.6.1.  Global Other End User Revenue and Growth Rate (2014-2018)

8.       Glaucoma Therapeutics Market, By Region

8.1.     Introduction

8.2.     Global Glaucoma Therapeutics Revenue and Market Share by Regions

8.2.1.  Global Glaucoma Therapeutics Revenue by Regions (2014-2018)

8.3.     North America Glaucoma Therapeutics by Countries

8.3.1.  North America Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)

8.3.2.  North America Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)

8.3.3.  United States

8.3.3.1.  United States Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.3.4.  Canada

8.3.4.1.  Canada Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.3.5.  Mexico

8.3.5.1.  Mexico Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.     Europe Glaucoma Therapeutics by Countries

8.4.1.  Europe Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)

8.4.2.  Europe Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)

8.4.3.  Germany

8.4.3.1.  Germany Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.4.  France

8.4.4.1.  France Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.5.  UK

8.4.5.1.  UK Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.6.  Russia

8.4.6.1.  Russia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.7.  Italy

8.4.7.1.  Italy Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.4.8.  Rest of Europe

8.4.8.1.  Rest of Europe Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.     Asia-Pacific Glaucoma Therapeutics by Countries

8.5.1.  Asia-Pacific Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)

8.5.2.  Asia-Pacific Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)

8.5.3.  China

8.5.3.1.  China Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.4.  Japan

8.5.4.1.  Japan Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.5.  Korea

8.5.5.1.  Korea Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.6.  India

8.5.6.1.  India Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.7.  Southeast Asia

8.5.7.1.  Southeast Asia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.5.8.  Rest of Asia-Pacific

8.5.8.1.  Rest of Asia-Pacific Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.     South America Glaucoma Therapeutics by Countries

8.6.1.  South America Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)

8.6.2.  South America Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)

8.6.3.  Brazil

8.6.3.1.  Brazil Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.4.  Argentina

8.6.4.1.  Argentina Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.5.  Columbia

8.6.5.1.  Columbia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.6.6.  Rest of South America

8.6.6.1.  Rest of South America Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.     Middle East and Africa Glaucoma Therapeutics by Countries

8.7.1.  Middle East and Africa Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)

8.7.2.  Middle East and Africa Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)

8.7.3.  Saudi Arabia

8.7.3.1.  Saudi Arabia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.4.  United Arab Emirates

8.7.4.1.  United Arab Emirates Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.5.  Egypt

8.7.5.1.  Egypt Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.6.  Nigeria

8.7.6.1.  Nigeria Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.7.  South Africa

8.7.7.1.  South Africa Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.8.  Turkey

8.7.8.1.  Turkey Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

8.7.9.  Rest of Middle East and Africa

8.7.9.1.  Rest of Middle East and Africa Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)

9.       Company Profiles

9.1.     Pfizer Inc.

9.1.1.  Business Overview

9.1.2.   Service Portfolio

9.1.3.  Strategic Developments

9.1.4.   Revenue and Market Share

9.2.     Valeant Pharmaceuticals International Inc.

9.2.1.  Business Overview

9.2.2.   Service Portfolio

9.2.3.  Strategic Developments

9.2.4.   Revenue and Market Share

9.3.     Novartis AG

9.3.1.  Business Overview

9.3.2.   Service Portfolio

9.3.3.  Strategic Developments

9.3.4.   Revenue and Market Share

9.4.     Allergan Inc.

9.4.1.  Business Overview

9.4.2.   Service Portfolio

9.4.3.  Strategic Developments

9.4.4.   Revenue and Market Share

9.5.     Aerie Pharmaceuticals

9.5.1.  Business Overview

9.5.2.   Service Portfolio

9.5.3.  Strategic Developments

9.5.4.   Revenue and Market Share

9.6.     Merck KGaA

9.6.1.  Business Overview

9.6.2.   Service Portfolio

9.6.3.  Strategic Developments

9.6.4.   Revenue and Market Share

9.7.     Santen Pharmaceutical Co. Ltd.

9.7.1.  Business Overview

9.7.2.   Service Portfolio

9.7.3.  Strategic Developments

9.7.4.   Revenue and Market Share

9.8.     Fera Pharmaceuticals LLC

9.8.1.  Business Overview

9.8.2.   Service Portfolio

9.8.3.  Strategic Developments

9.8.4.   Revenue and Market Share

9.9.     Aristo Pharmaceuticals Pvt. Ltd.

9.9.1.  Business Overview

9.9.2.   Service Portfolio

9.9.3.  Strategic Developments

9.9.4.   Revenue and Market Share

9.10. Teva Pharmaceutical Industries Ltd.

9.10.1.      Business Overview

9.10.2.       Service Portfolio

9.10.3.      Strategic Developments

9.10.4.       Revenue and Market Share

10.    Global Glaucoma Therapeutics Market Competition, by Manufacturer

10.1. Global Glaucoma Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

10.2. Global Glaucoma Therapeutics Price By Region (2016-2017)

10.3. Top 5 Glaucoma Therapeutics Manufacturer Market Share

10.4. Market Competition Trend

11.    Glaucoma Therapeutics Market Forecast (2018-2025)

11.1. Global Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)

11.2. Glaucoma Therapeutics Market Forecast by Regions (2018-2025)

11.2.1.      North America Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.1.1. United States Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.1.2. Canada Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.1.3. Mexico Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.      Europe Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.1. Germany Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.2. France Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.3. UK Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.4. Russia Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.5. Italy Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.2.6. Rest of Europe Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.      Asia-Pacific Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.1. China Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.2. Japan Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.3. Korea Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.4. India Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.5. Southeast Asia Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.3.6. Rest of Asia-Pacific Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.4.      South America Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.4.1. Brazil Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.4.2. Argentina Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.4.3. Columbia Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.4.4. Rest of South America Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.      Middle East and Africa Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.1. Saudi Arabia Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.2. United Arab Emirates Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.3. Egypt Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.4. Nigeria Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.5. South Africa Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.6. Turkey Glaucoma Therapeutics Market Forecast (2018-2025)

11.2.5.7. Rest of Middle East and Africa Glaucoma Therapeutics Market Forecast (2018-2025)

11.3. Glaucoma Therapeutics Market Forecast by Disease Type (2018-2025)

11.3.1.      Glaucoma Therapeutics Forecast by Disease Type (2018-2025)

11.3.2.      Glaucoma Therapeutics Market Share Forecast by Disease Type (2018-2025)

11.4. Glaucoma Therapeutics Market Forecast by Drug Class (2018-2025)

11.4.1.      Glaucoma Therapeutics Forecast by Drug Class (2018-2025)

11.4.2.      Glaucoma Therapeutics Market Share Forecast by Drug Class (2018-2025)

11.5. Glaucoma Therapeutics Market Forecast by End User (2018-2025)

11.5.1.      Glaucoma Therapeutics Forecast by End User (2018-2025)

11.5.2.      Glaucoma Therapeutics Market Share Forecast by End User (2018-2025)


List of Tables

List of Tables and Figures:

Figure United States Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Canada Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Mexico Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Germany Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure France Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure UK Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Russia Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Italy Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Europe Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure China Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Japan Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Korea Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure India Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Southeast Asia Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Asia-Pacific Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Brazil Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Argentina Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Columbia Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of South America Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Saudi Arabia Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure United Arab Emirates Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Egypt Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Nigeria Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure South Africa Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Turkey Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Figure Rest of Middle East and Africa Glaucoma Therapeutics Revenue (Million USD) and Growth Rate (2014-2025)
Table Global Glaucoma Therapeutics Revenue and Revenue Share by Disease Type (2014-2018)
Figure Global Primary Angle Closure Glaucoma (PACG) Revenue and Growth Rate (2014-2018)
Figure Global Primary Open Angle Glaucoma (POAG) Revenue and Growth Rate (2014-2018)
Table Global Glaucoma Therapeutics Revenue and Revenue Share by Drug Class (2014-2018)
Figure Global Fixed-Dose Combinations Revenue and Growth Rate (2014-2018)
Figure Global Alpha Adrenergic Agonist Revenue and Growth Rate (2014-2018)
Figure Global Combined Medication Revenue and Growth Rate (2014-2018)
Figure Global Beta Blockers Revenue and Growth Rate (2014-2018)
Figure Global Cholinergic Revenue and Growth Rate (2014-2018)
Figure Global Prostaglandin Analogs Revenue and Growth Rate (2014-2018)
Figure Global Carbonic Anhydrase Inhibitor Revenue and Growth Rate (2014-2018)
Table Global Glaucoma Therapeutics Revenue and Revenue Share by End User (2014-2018)
Figure Global Ambulatory Surgical Centers Revenue and Growth Rate (2014-2018)
Figure Global Ophthalmic Clinics Revenue and Growth Rate (2014-2018)
Figure Global Hospitals Revenue and Growth Rate (2014-2018)
Figure Global Other End User Revenue and Growth Rate (2014-2018)
Table Global Glaucoma Therapeutics Revenue by Regions (2014-2018)
Figure North America Glaucoma Therapeutics Growth Rate (2014-2018)
Figure North America Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)
Figure North America Glaucoma Therapeutics by Countries (2014-2018)
Figure North America Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)
Figure United States Glaucoma Therapeutics Growth Rate (2014-2018)
Figure United States Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Canada Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Canada Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Mexico Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Mexico Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Europe Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Europe Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)
Figure Europe Glaucoma Therapeutics by Countries (2014-2018)
Figure Europe Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)
Figure Germany Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Germany Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure France Glaucoma Therapeutics Growth Rate (2014-2018)
Figure France Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure UK Glaucoma Therapeutics Growth Rate (2014-2018)
Figure UK Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Russia Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Russia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Italy Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Italy Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Europe Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Rest of Europe Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Asia-Pacific Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Asia-Pacific Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)
Figure Asia-Pacific Glaucoma Therapeutics by Countries (2014-2018)
Figure Asia-Pacific Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)
Figure China Glaucoma Therapeutics Growth Rate (2014-2018)
Figure China Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Japan Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Japan Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Korea Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Korea Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure India Glaucoma Therapeutics Growth Rate (2014-2018)
Figure India Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Southeast Asia Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Southeast Asia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Asia-Pacific Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Rest of Asia-Pacific Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure South America Glaucoma Therapeutics Growth Rate (2014-2018)
Figure South America Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)
Figure South America Glaucoma Therapeutics by Countries (2014-2018)
Figure South America Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)
Figure Brazil Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Brazil Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Argentina Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Argentina Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Columbia Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Columbia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of South America Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Rest of South America Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Middle East and Africa Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Middle East and Africa Glaucoma Therapeutics Revenue and Growth Rate (2014-2018)
Figure Middle East and Africa Glaucoma Therapeutics by Countries (2014-2018)
Figure Middle East and Africa Glaucoma Therapeutics Revenue (Million USD) by Countries (2014-2018)
Figure Saudi Arabia Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Saudi Arabia Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure United Arab Emirates Glaucoma Therapeutics Growth Rate (2014-2018)
Figure United Arab Emirates Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Egypt Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Egypt Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Nigeria Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Nigeria Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure South Africa Glaucoma Therapeutics Growth Rate (2014-2018)
Figure South Africa Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Turkey Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Turkey Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Figure Rest of Middle East and Africa Glaucoma Therapeutics Growth Rate (2014-2018)
Figure Rest of Middle East and Africa Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2014-2018)
Table Pfizer Inc. Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Valeant Pharmaceuticals International Inc. Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Novartis AG Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Allergan Inc. Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Aerie Pharmaceuticals Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Merck KGaA Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Santen Pharmaceutical Co. Ltd. Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Fera Pharmaceuticals LLC Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Aristo Pharmaceuticals Pvt. Ltd. Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Teva Pharmaceutical Industries Ltd. Glaucoma Therapeutics Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Glaucoma Therapeutics Market Share by Manufacturer
Figure Global Glaucoma Therapeutics Revenue and Market Share by Manufacturer
Table Global Glaucoma Therapeutics Price by Region (2016-2017)
Figure Top 5 Glaucoma Therapeutics Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Glaucoma Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Glaucoma Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Glaucoma Therapeutics Market Forecast (2018-2025)
Figure United States Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Canada Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Mexico Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Europe Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Germany Glaucoma Therapeutics Market Forecast (2018-2025)
Figure France Glaucoma Therapeutics Market Forecast (2018-2025)
Figure UK Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Russia Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Italy Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Glaucoma Therapeutics Market Forecast (2018-2025)
Figure China Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Japan Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Korea Glaucoma Therapeutics Market Forecast (2018-2025)
Figure India Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Glaucoma Therapeutics Market Forecast (2018-2025)
Figure South America Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Brazil Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Argentina Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Columbia Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Glaucoma Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Egypt Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Nigeria Glaucoma Therapeutics Market Forecast (2018-2025)
Figure South Africa Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Turkey Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Glaucoma Therapeutics Market Forecast (2018-2025)
Figure Global Glaucoma Therapeutics Forecast by Disease Type (2018-2025)
Figure Global Glaucoma Therapeutics Market Share Forecast by Disease Type (2018-2025)
Figure Global Glaucoma Therapeutics Forecast by Disease Type (2018-2025)
Figure Global Glaucoma Therapeutics Forecast by Drug Class (2018-2025)
Figure Global Glaucoma Therapeutics Market Share Forecast by Drug Class (2018-2025)
Figure Global Glaucoma Therapeutics Forecast by Drug Class (2018-2025)
Figure Global Glaucoma Therapeutics Forecast by End User (2018-2025)
Figure Global Glaucoma Therapeutics Market Share Forecast by End User (2018-2025)

Figure Global Glaucoma Therapeutics Forecast by End User (2018-2025)


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*